Browse TAF5L

Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF04494 WD40 associated region in TFIID subunit
PF00400 WD domain
Function

Functions as a component of the PCAF complex. The PCAF complex is capable of efficiently acetylating histones in a nucleosomal context. The PCAF complex could be considered as the human version of the yeast SAGA complex.

> Gene Ontology
 
Biological Process GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0043543 protein acylation
GO:0043966 histone H3 acetylation
Molecular Function GO:0003713 transcription coactivator activity
GO:0004402 histone acetyltransferase activity
GO:0008080 N-acetyltransferase activity
GO:0016407 acetyltransferase activity
GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0034212 peptide N-acetyltransferase activity
GO:0061733 peptide-lysine-N-acetyltransferase activity
Cellular Component GO:0000123 histone acetyltransferase complex
GO:0000428 DNA-directed RNA polymerase complex
GO:0005667 transcription factor complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030880 RNA polymerase complex
GO:0030914 STAGA complex
GO:0031248 protein acetyltransferase complex
GO:0033276 transcription factor TFTC complex
GO:0044798 nuclear transcription factor complex
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0070461 SAGA-type complex
GO:0090575 RNA polymerase II transcription factor complex
GO:1902493 acetyltransferase complex
> KEGG and Reactome Pathway
 
KEGG hsa03022 Basal transcription factors
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214847: HATs acetylate histones
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TAF5L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TAF5L in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TAF5L in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1360.405
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2950.85
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0220.984
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0180.935
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2330.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2540.92
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1630.621
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0810.956
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4420.786
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1330.899
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6420.671
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0590.316
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TAF5L in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAF5L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAF5L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAF5L.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAF5L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TAF5L expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TAF5L and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTAF5L
NameTAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa
Aliases PAF65B; PCAF associated factor 65 beta; TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-assoc ......
Chromosomal Location1q42.11-q42.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TAF5L collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.